Fever as the only manifestation of hypersensitivity reactions associated with oxaliplatin in a patient with colorectal cancer Oxaliplatin-induced hypersensitivity reaction

被引:11
作者
Saif, M. Wasif
Roy, Shailja
Ledbetter, Leslie
Madison, Jennifer
Syrigos, Kostas
机构
[1] Yale Univ, Sch Med, Sect Med Oncol, New Haven, CT 06520 USA
[2] Univ Alabama, Birmingham, AL USA
[3] Sotiria Gen Hosp, Athens Med Sch, Athens, Greece
关键词
oxaliplatin; hypersensitivity reaction; fever; colon cancer;
D O I
10.3748/wjg.v13.i39.5277
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Hypersensitivity reactions (HSR) to oxaliplatin in patients with colorectal cancer include facial flushing, erythema, pruritis, fever, tachycardia, dyspnea, tongue swelling, rash/hives, headache, chills, weakness, vomiting, burning sensations, dizziness, and edema. We report a patient with fever as the sole manifestation of initial HSR, review the literature and discuss the management of HSR. A 57-year-old female with T3N2M0 rectal adenocarcinoma received modified FOLFOX-6. She tolerated the first 8 cycles without any toxicities except grade 1 peripheral neuropathy and nausea. During 9(th) and 10(th) infusions, she developed fever to a maximum of 38.3 degrees C with stable hemodynamic status despite medications. During 11(th) infusion, she developed grade 3 HSR consisting of symptomatic bronchospasm, hypotension, nausea, vomiting, cough, and fever. On examination, she was pale, cyanotic, with a temperature of 38.8 degrees C, BP dropped to 95/43 mm Hg, pulse of 116/min and O-2 saturation of 88%-91%. She was hospitalized for management and recovered in 24 h. Fever alone is not a usual symptom of oxaliplatin HSR. It may be indicative that the patient may develop serious reactions subsequently, as did our patient who developed hypotension with the third challenge. Treatment and prevention consists of slowing the infusion rate, use of steroids and antagonists of Type 1 and 2 histamine receptor antagonists, whereas desensitization could help to provide the small number of patients who experience severe HSR with the ability to further receive an effective therapy for their colorectal cancer. (C) 2007 WJG. All rights reserved.
引用
收藏
页码:5277 / 5281
页数:5
相关论文
共 50 条
  • [41] Mechanism of trifluorothymidine potentiation of oxaliplatin-induced cytotoxicity to colorectal cancer cells
    Temmink, O. H.
    Hoebe, E. K.
    van der Born, K.
    Ackland, S. P.
    Fukushima, M.
    Peters, G. J.
    BRITISH JOURNAL OF CANCER, 2007, 96 (02) : 231 - 240
  • [42] ATM Is Required for the Repair of Oxaliplatin-Induced DNA Damage in Colorectal Cancer
    Bakkenist, Christopher J.
    Lee, James J.
    Schmitz, John C.
    CLINICAL COLORECTAL CANCER, 2018, 17 (04) : 255 - 257
  • [43] Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients
    Velasco, Roser
    Bruna, Jordi
    Briani, Chiara
    Argyriou, Andreas A.
    Cavaletti, Guido
    Alberti, Paola
    Frigeni, Barbara
    Cacciavillani, Mario
    Lonardi, Sara
    Cortinovis, Diego
    Cazzaniga, Marina
    Santos, Cristina
    Kalofonos, Haralabos P.
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2014, 85 (04) : 392 - 398
  • [44] Mechanism of trifluorothymidine potentiation of oxaliplatin-induced cytotoxicity to colorectal cancer cells
    O H Temmink
    E K Hoebe
    K van der Born
    S P Ackland
    M Fukushima
    G J Peters
    British Journal of Cancer, 2007, 96 : 231 - 240
  • [45] Oxaliplatin re-challenge in colorectal cancer patients with clinically-significant oxaliplatin-induced peripheral neurotoxicity
    Argyriou, Andreas
    Anastopoulou, Garifallia
    Bruna, Jordi
    Velasco, Roser
    Kalofonos, Haralabos
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2020, 25 (04) : 458 - 458
  • [46] Oxaliplatin-Free Interval as a Risk Factor for Hypersensitivity Reaction among Colorectal Cancer Patients Treated with FOLFOX
    Mori, Yukiko
    Nishimura, Takafumi
    Kitano, Toshiyuki
    Yoshimura, Ken-ichi
    Matsumoto, Shigemi
    Kanai, Masashi
    Hazama, Megumi
    Ishiguro, Hiroshi
    Nagayama, Satoshi
    Yanagihara, Kazuhiro
    Teramukai, Satoshi
    Chiba, Tsutomu
    Sakai, Yoshiharu
    Fukushima, Masanori
    ONCOLOGY, 2010, 79 (1-2) : 136 - 143
  • [47] Phytochemicals of Cinnamomi Cortex: Cinnamic Acid, but not Cinnamaldehyde, Attenuates Oxaliplatin-Induced Cold and Mechanical Hypersensitivity in Rats
    Chae, Hyeon Kyeong
    Kim, Woojin
    Kim, Sun Kwang
    NUTRIENTS, 2019, 11 (02):
  • [48] Case report: Tocilizumab for hypersensitivity reaction after oxaliplatin in a patient with NK/T-cell lymphoma
    Liao, Juanyan
    Jiang, Ming
    FRONTIERS IN PHARMACOLOGY, 2025, 15
  • [49] Oxaliplatin-Induced Chronic Peripheral Neurotoxicity: A Prospective Analysis in Patients with Colorectal Cancer
    Baek, Kyung Kee
    Lee, Jeeyun
    Park, Se Hoon
    Park, Joon Oh
    Park, Young Suk
    Lim, Ho Yeong
    Kang, Won Ki
    Cho, Yong Beom
    Yun, Seong Hyeon
    Kim, Hee Cheol
    Lee, Woo Yong
    Chun, Ho-Kyung
    CANCER RESEARCH AND TREATMENT, 2010, 42 (04): : 185 - 190
  • [50] A descriptive study of persistent oxaliplatin-induced peripheral neuropathy in patients with colorectal cancer
    Sina Vatandoust
    Rohit Joshi
    Kenneth B. Pittman
    Adrian Esterman
    Vy Broadbridge
    Jacqueline Adams
    Nimit Singhal
    Susan Yeend
    Timothy Jay Price
    Supportive Care in Cancer, 2014, 22 : 513 - 518